Bli medlem
Bli medlem

Du är här

2021-07-23

DBP International AB: clinical batch of SI-053 has been manufactured for the upcoming clinical trial phase 1

Double Bond Pharmaceutical International AB (publ) ("DBP") takes a step closer to the start of the Phase 1 clinical trial of its frontline product SI-053 in patients with glioblastoma - batch of SI-053 has been manufactured for the upcoming Phase 1 clinical trial of the EU GMP certified manufacturer.

This material will be used in the upcoming Phase 1 clinical trial which is an open dose escalation and dose expansion study to estimate maximum tolerated dose (MTD), identify dose limiting toxicities (DLT) and recommended phase 2 dose (RP2D) of SI-053.

"This is another important part of the product development which means that we will deliver a sterile and safe product to the patients, according to EU requirements" - comments Igor Lokot, CEO of DBP.

 

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.